Dr. Yunfeng Li 李云峰
Chief Physician
Medical Oncology (III), Yunnan Cancer Hospital, Kunming
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical and comprehensive treatment of abdominal tumors, including colorectal, gastric, liver, pancreatic, and duodenal cancers, with a special focus on colorectal cancer diagnosis and treatment.
Dr. Li is Director of the Colorectal Cancer Center at Yunnan Cancer Hospital and a doctoral supervisor. With over ten years of experience in abdominal tumor surgery, research, and teaching, Dr. Li performed Yunnan's first laparoscopic radical rectal cancer surgery. Dr. Li has co-authored two oncology textbooks, published over 20 papers, and received a Yunnan Provincial Science and Technology Progress Award.
Professional roles
- Member, Chinese Medical Association
- Member, Colorectal Cancer Professional Committee, China Anti-Cancer Association
- Member, Digestive Endoscopy Society of Yunnan Province, Chinese Medical Association
- Member, European Society for Medical Oncology (ESMO)
Name order: in Chinese the family name comes first (Li Yunfeng). Papers usually list the name as Yunfeng Li or Li Y.
Selected publications
53 papers on PubMed matched by name and affiliation; 24 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Transl Med, 2026 (senior author): Dual immunosuppression mechanism induced by PTP1B in colorectal cancer: upregulation of PD-L1 by FOXO1/miR-34C/c-MYC axis and inhibition of the infiltration of CD8(+) T cell by downregulating of CXCL11. PubMed 42050706
- Biochem Genet, 2025 (senior author): Retraction Note: Sodium Butyrate Inhibits the Malignant Proliferation of Colon Cancer Cells via the miR-183/DNAJB4 Axis. PubMed 41060569
- Int J Colorectal Dis, 2025 (senior author): ERO1α regulates colon cancer progression and 5-FU resistance through the miR-451a/ARF1 axis. PubMed 40835727
- Front Biosci (Landmark Ed), 2024 (senior author): Dual Role of Lysosome in Cancer Development and Progression. PubMed 39614447
- Biochem Genet, 2024 (senior author): Sodium Butyrate Inhibits the Malignant Proliferation of Colon Cancer Cells via the miR-183/DNAJB4 Axis. PubMed 38244156
- Heliyon, 2024 (senior author): Identification of lncRNA-mRNA network linking ferroptosis and immune infiltration to colon adenocarcinoma suppression. PubMed 39050439
- Target Oncol, 2024 (first author): Correction to: Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer. PubMed 38833122
- Target Oncol, 2024 (first author): Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer. PubMed 38691294
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion